eTable 1. Marginal Structural Linear Regression models: Models for the construction of inverse probability of censoring weights to evaluate the effect of selecting different covariates and covariates forms on the stabilized weights and effect estimates of FTC-TDF* versus placebo on the risk for ≥25% eGFR decline from baseline Model The primary approach was a per-protocol analysis censoring any visits occurring after >4 consecutive weeks off study medication. a MSM: Marginal structural models. The marginal structural models used time-dependent stabilized weights (mean 1.00, range 0.99-1.03), which were estimated using pooled logistic regression models with censoring indicator as the outcome and prior visit histories of the time-varying covariates, creatinine clearance and serum creatinine, as 3 knot restricted cubic splines at 5th, 50th, and 95th percentiles plus treatment arm, sex, site, age, baseline eGFR, and time since randomization as part of the numerator model. b Intention-to-treat analysis includes all randomized participants with at least one post-randomization serum creatinine measurement regardless of time off study medication, for data collected through July 2011.
c ITT extended follow-up analysis is an intention-to-treat approach that includes the additional follow-up time of persons randomized to TDF and FTC-TDF groups beyond July 2011 when the placebo arm was discontinued. During the extended follow-up, both investigators and participants remained blinded to the type of PrEP drug the participant was receiving.
Placebo groups contributed records only up to July 2011. eTable 4. Absolute incidence rates and hazard ratios for a ≥25% eGFR decline from baseline overall and among subgroups, according to treatment study group.
No. of events/total person-years Absolute incidence rate difference per 100 person-years a (95%CI)

Adjusted hazard ratio e (95%CI); p-value
Approach
FTC-TDF TDF Placebo FTC-TDF vs. Placebo
protocol analysis (i.e 1.3% for TDF, 1.3%, and 0.9% for the placebo, by 12 months; 1.9% for TDF, 2.3%, and 1.3% for the placebo by 24 months; and 2.2% for TDF, 2.8%, and 2.2% by 36 months). During the additional follow-up both the investigators and participants remained blinded to the type of PrEP drug the participant was receiving. Placebo groups contributed records only up to July 2011. e Hazard ratios estimated using Cox proportional hazards models stratified according sex, age groups, and site to account for laboratory heterogeneity in serum creatinine estimation. For subgroups, the group evaluated was dropped from the stratification. All subgroups estimates are for the per-protocol approach. Models were adjusted for baseline eGFR as 3 knot restricted cubic splines at 5 th , 50 th , and 95 th percentiles. All p-values are two-sided testing the null hypothesis of no treatment effects. FTC denotes emtricitabine and TDF denotes tenofovir disoproxil fumarate.
